Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H34ClN3O4 |
| Molecular Weight | 488.019 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)[C@H]1CC[C@@H](CC1)[C@@]2(C)OC3=C(Cl)C=C(C(=O)NCC4=C(C)C=C(C)NC4=O)C(C)=C3O2
InChI
InChIKey=SSDRNUPMYCFXGM-UYPAYLBCSA-N
InChI=1S/C26H34ClN3O4/c1-14-11-15(2)29-25(32)20(14)13-28-24(31)19-12-21(27)23-22(16(19)3)33-26(4,34-23)17-7-9-18(10-8-17)30(5)6/h11-12,17-18H,7-10,13H2,1-6H3,(H,28,31)(H,29,32)/t17-,18-,26-/m1/s1
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1500 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37565616/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VALEMETOSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
2230 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36150143/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALEMETOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10800 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37565616/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VALEMETOSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
18100 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36150143/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALEMETOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
20.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37565616/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VALEMETOSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
9.46 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36150143/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALEMETOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/37565616/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VALEMETOSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C471
Created by
admin on Mon Mar 31 22:45:45 GMT 2025 , Edited by admin on Mon Mar 31 22:45:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C127114
Created by
admin on Mon Mar 31 22:45:45 GMT 2025 , Edited by admin on Mon Mar 31 22:45:45 GMT 2025
|
PRIMARY | |||
|
10747
Created by
admin on Mon Mar 31 22:45:45 GMT 2025 , Edited by admin on Mon Mar 31 22:45:45 GMT 2025
|
PRIMARY | |||
|
1809336-39-7
Created by
admin on Mon Mar 31 22:45:45 GMT 2025 , Edited by admin on Mon Mar 31 22:45:45 GMT 2025
|
PRIMARY | |||
|
60RD0234VE
Created by
admin on Mon Mar 31 22:45:45 GMT 2025 , Edited by admin on Mon Mar 31 22:45:45 GMT 2025
|
PRIMARY | |||
|
100000181197
Created by
admin on Mon Mar 31 22:45:45 GMT 2025 , Edited by admin on Mon Mar 31 22:45:45 GMT 2025
|
PRIMARY | |||
|
126481870
Created by
admin on Mon Mar 31 22:45:45 GMT 2025 , Edited by admin on Mon Mar 31 22:45:45 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)